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The Polish Physician’s and Dentist’s Profession Act and
Polish Pharmaceutical Law oblige physicians to prescribing
drugs strictly in line with the official indications listed in
the Summaries of Product Characteristic (SPC).
Prescriptions beyond SPC (’off-label’) may be interpreted
as ‘medical experiments’ with legal and financial liability
resting solely with the doctor, the reimbursement is also
denied. The aimof the study was to analyze discrepancies
between up-to-date expert guidelines for treating atopic
eczema (AE), indications listed in SPC, reimbursement pol-
icy, and scientific evidence for the efficacy of recommended
drugs. Expert recommendations for the treatment of AE
were confronted with SPC of recommended drugs and
their reimbursement scheme. A systematic review of
clinical trials was done, with their quality assessed using
the GRADE tool. Among drugs recommended by experts
for the treatment of AE, 484 medicinal products were
licensed for use in Poland, including 89 with official
indication for AE. Of these, clinical trials confirmed efficacy
of active components of 36 topical or systemic calcineurin
inhibitors and 19 topical glucocorticoid preparations.
Thirty preparations for AE were reimbursed, including 19
recommended by experts and confirmed effective. Further
75 products with active substances recommended and
effective were licensed for use in Poland, but not for AE.
We conclude that in the pharmacotherapy of atopic
eczema there are considerable discrepancies between
expert recommendations, scientific evidence for the effec-
tiveness of recommended drugs, and the acceptable uses of
the drugs determined by the Summaries of Product
Characteristics.
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